US EditionFDA Approves Wegovy for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease
6 Articles
6 Articles
Food and Drug Administration has authorised the use of Wegovy slimming drug to treat severe liver disease in the United States
The Food and Drug Administration (FDA) approved on Friday Wegovy, a slimming drug, to treat an increasingly frequent liver disease. Approximately 15 million people — 6 percent of adults in the United States — suffer from steathepatitis associated with metabolic dysfunction, known as MASH, by its acronym in English. Rates of this disease are increasing. The condition occurs when fat builds up in the liver, which can trigger scars, cell damage, an…
FDA approves Wegovy for MASH with moderate to advanced liver fibrosis
The FDA has approved Wegovy (semaglutide) injection 2.4 mg to treat adults with MASH with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver, in conjunction with a reduced calorie diet and increased physical activity. This indication is approved based on improvement of MASH and liver scarring (fibrosis). There is an ongoing study to confirm the clinical benefit of Wegovy in adults with MASH.This FDA approval is b…
Wegovy has been approved for use among the growing number of Americans suffering from liver disease associated with metabolic dysfunction. The Food and Drug Administration (FDA) approved Wegovy, a weight-loss drug, on Friday to treat an increasingly common liver disease. Approximately 15 million people—the […]
The U.S. Food and Drug Administration (FDA) has announced a new additional indication of 'Wegovy' for the treatment of a liver disease, which adds to that of type 2 diabetes and obesity. A news story that coincides with the announcement by pharmaceutical company Novo Nordisk related to the reduction of the price of 'Ozempic' for patients in the U.S. not covered by health insurance. Specifically, the FDA has approved an additional indication of '…
FDA Approves Wegovy for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease
The U.S. Food and Drug Administration (FDA) has approve […] The post FDA Approves Wegovy for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease first appeared on GeneOnline News. The post FDA Approves Wegovy for Treating Metabolic Dysfunction-Associated Steatotic Liver Disease appeared first on GeneOnline News.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
